# Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy

> **NCT00532064** · — · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 55 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT00532064
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2007-09-12
- **Primary completion:** 2018-05-02
- **Final completion:** 2018-05-02
- **Target enrollment:** 55 (ACTUAL)
- **Why stopped:** Terminated per PI's request
- **Last updated:** 2020-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00532064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00532064, "Cardiac Biomarkers in Early Detection of Cardiotoxicity in Patients Receiving Sunitinib or Sorafenib Chemotherapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00532064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*